ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Disproportionality analysis of ventricular extrasystoles reported with semaglutide in VigiBase and the FDA Adverse Event Monitoring System.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Semaglutide is widely used to treat type 2 diabetes and obesity and to reduce cardiovascular risk. However, its association with cardiac rhythm-related adverse-event reporting in routine clinical practice remains incompletely characterized. To investigate cardiovascular and rhythm-related adverse-event reporting associated with semaglutide, with a focus on ventricular extrasystoles, we conducted a disproportionality analysis of individual case safety reports from VigiBase and the FDA Adverse Event Monitoring System (AEMS; formerly the FDA Adverse Event Reporting System [FAERS]). Reports were included when semaglutide was recorded as a suspected drug, according to database-specific criteria. Cardiovascular outcomes were identified using Medical Dictionary for Regulatory Activities Preferred Terms. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated. A cross-database reporting signal was defined as at least three semaglutide-associated reports and a lower 95% CI bound exceeding 1 in each database. After deduplication and application of the predefined inclusion criteria, 1980 semaglutide-associated cardiovascular reports from VigiBase and 1754 from AEMS were included. Among the screened cardiovascular and rhythm-related preferred terms, ventricular extrasystoles was the only term that met the prespecified signal criterion in both databases. Ventricular extrasystoles, clinically corresponding to premature ventricular contractions, showed disproportionate reporting in VigiBase (ROR 1.77, 95% CI 1.31-2.40) and AEMS (ROR 1.37, 95% CI 1.00-1.88; unrounded lower CI bound > 1). Ventricular extrasystoles showed a consistent disproportionality signal across VigiBase and AEMS. Although spontaneous reporting data cannot establish incidence, causality, or prognostic significance, this finding warrants prospective investigation using systematic electrocardiographic assessment and ambulatory rhythm monitoring.
Indexed as
Identifiers
42993217What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.